Wurm, S; Moritz, JM; Petzer, V; Wolf, D; Gleixner, KV; Sperr, WR; Groiss, C; Machherndl-Spandl, S; Eisenwort, G; Koller, E; Schoeche, J; Petrasch, C; Singer, J; Mayer, DM; Pregartner, G; Heine, A; Wölfler, A; Sill, H; Reinisch, A; Zebisch, A.
Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study.
Blood Cancer J. 2025; 15(1): 175
Doi: 10.1038/s41408-025-01396-5
PubMed
FullText
FullText_MUG